Article Text

PDF
MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)
  1. M L Hetland1,
  2. B Ejbjerg1,2,
  3. K Hørslev-Petersen3,
  4. S Jacobsen4,
  5. A Vestergaard5,
  6. A G Jurik6,
  7. K Stengaard-Pedersen7,
  8. P Junker8,
  9. T Lottenburger3,
  10. I Hansen7,
  11. L S Andersen3,
  12. U Tarp7,
  13. H Skjødt1,
  14. J K Pedersen3,
  15. O Majgaard1,
  16. A J Svendsen3,
  17. T Ellingsen7,
  18. H Lindegaard8,
  19. A F Christensen8,
  20. J Vallø9,
  21. T Torfing10,
  22. E Narvestad5,
  23. H S Thomsen11,
  24. M Østergaard3,
  25. and the CIMESTRA study group
  1. 1
    Department of Rheumatology, Copenhagen University Hospital, Hvidovre, Denmark
  2. 2
    Department of Rheumatology, Copenhagen University Hospital, Herlev, Denmark
  3. 3
    Department of Rheumatology, Rheumatism Hospital, University of Southern Denmark, Gråsten, Denmark
  4. 4
    Department of Rheumatology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
  5. 5
    Department of Radiology, Copenhagen University Hospital, Hvidovre, Denmark
  6. 6
    Department of Radiology, Århus University Hospital, Århus, Denmark
  7. 7
    Department of Rheumatology, Århus University Hospital, Århus, Denmark
  8. 8
    Department of Rheumatology, Odense University Hospital, Odense, Denmark
  9. 9
    Department of Radiology, Aabenraa Sygehus, Aabenraa, Denmark
  10. 10
    Department of Radiology, Odense University Hospital, Odense, Denmark
  11. 11
    Department of Radiology, Copenhagen University Hospital, Herlev, Denmark
  1. Dr K Hørslev-Petersen, Rheumatism Hospital, University of Southern Denmark, Toldbodgade 3, DK-6300 Gråsten, Denmark; khorslevpetersen{at}gigtforeningen.dk

Abstract

Objective: To identify predictors of radiographic progression in a 2-year randomised, double-blind, clinical study (CIMESTRA) of patients with early rheumatoid arthritis (RA).

Methods: Patients with early RA (n = 130) were treated with methotrexate, intra-articular betamethasone and ciclosporin/placebo-ciclosporin. Baseline magnetic resonance imaging (MRI) of the wrist (wrist-only group, n = 130) or MRI of wrist and metacarpophalangeal (MCP) joints (wrist+MCP group, n = 89) (OMERACT RAMRIS), x-ray examination of hands, wrists and forefeet (Sharp/van der Heijde Score (TSS)), Disease Activity Score (DAS28), anti-cyclic citrullinated peptide antibodies (anti-CCP), HLA-DRB1-shared epitope (SE) and smoking status were assessed. Multiple regression analysis was performed with delta-TSS (0–2 years) as dependent variable and baseline DAS28, TSS, MRI bone oedema score, MRI synovitis score, MRI erosion score, anti-CCP, smoking, SE, age and gender as explanatory variables.

Results: Baseline values: median DAS28 5.6 (range 2.4–8.0); anti-CCP positive 61%; radiographic erosions 56%. At 2 years: DAS28 2.0 (0.5–5.7), in DAS remission: 56%, radiographic progression 26% (wrist+MCP group, similar for wrist-only group). MRI bone oedema score was the only independent predictor of delta-TSS (wrist+MCP group: coefficient = 0.75 (95% CI 0.55 to 0.94), p<0.001; wrist-only group: coefficient = 0.59 (95% CI 0.40 to 0.77), p<0.001). Bone oedema score explained 41% of the variation in the progression of TSS (wrist+MCP group), 25% in wrist-only group (Pearson’s r = 0.64 and r = 0.50, respectively). Results were confirmed by sensitivity analyses.

Conclusion: In a randomised controlled trial aiming at remission in patients with early RA, baseline RAMRIS MRI bone oedema score of MCP and wrist joints (and of wrist only) was the strongest independent predictor of radiographic progression in hands, wrists and forefeet after 2 years. MRI synovitis score, MRI erosion score, DAS28, anti-CCP, SE, smoking, age and gender were not independent risk factors.

Trial registration number: NCT00209859.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None.

  • Funding: The study was supported by a grant from The Danish Rheumatism Association.

  • Ethics approval: Approved by the national health authorities and ethics committees (reference number M-1959-98).

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.